Please login to the form below
Access to Medicines Index
This page shows the latest Access to Medicines Index news and features for those working in and with pharma, biotech and healthcare.
GSK tops Access to Medicines Index for fifth time running
The company topped the Access to Medicines Index for the fifth consecutive time after the biannual good practice report found it “the most access-oriented company” of the top 20 pharma ... The Access to Medicines Index 2016. View the Access to
Latest news
-
GSK unveils access plan for low-income countries
The company's chief executive Sir Andrew Witty - who will step down next year - announced the measure just ahead of the UN High Level Panel on Access to Medicines yesterday. ... GSK already has a good track record on medicines access, ranking at number
-
Novartis to make 15 drugs available at $1 a month
Novartis has launched an access programme aimed at low-and middle-income countries that will make 15 of its medicines for chronic diseases available at a knockdown price. ... Novartis was ranked fourth in the 2014 Access to Medicines Index funded by the
-
GSK tops pharma access to medicines table
The biannual Access To Medicines Index (ATMI) - which is funded by the Bill &Melinda Gates Foundation and the UK and Dutch governments - puts GlaxoSmithKline at the top of its rankings in ... The Access to Medicines Index 2014. "In recent years,
-
EU pharma heading efforts to get drugs to the poor
The Access to Medicines Index was launched on June 16 and shows that only one US manufacturer, Merck &Co, which came third, has made it into the top seven. ... Leereveld said that the most striking fact is that the index, set up by the Access to Medicine
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Twist Health
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
